We are pleased to share the results of the second edition of the Financial Times and Statista "Europe's Long-term Growth Champions" ranking, which celebrates resilience and innovation in Europe.

This ranking identifies the 300 European companies that achieved the highest Compound Annual Growth Rate (CAGR) in revenue over a decade, from 2014 to 2024, a period marked by momentous challenges such as the post-pandemic recession.

In this context, Kolinpharma^® ranks 14th in the overall ranking, but more importantly, it ranks first in Europe in the Health Care & Life Sciences sector and second among Italian companies.

This ranking not only reflects economic size, but also rewards the ability to innovate and financial transparency of high-growth companies: distinctive and key aspects for Kolinpharma^®, as it has always been.